Has Jovita Crasta received payments from drug or device companies?

Yes. Drug and device makers reported $618,708 in general payments to Jovita Crasta across 578 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jovita Crasta did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jovita Crasta come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jovita Crasta

Psychiatry · Baldwin, NYNPI 1053302711

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $489,047 of the $618,708 with a category attached, or 79.0%. Neurocrine Biosciences, Inc. accounts for 92.6% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $150,238, 3.8 times the $39,758 reported in 2019. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$618,708in general payments, 2019–2025

Across 578 payments — averaging $1070.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Neurocrine Biosciences, Inc.$573K
E.r. Squibb & Sons, L.L.C.$38K
Sunovion Pharmaceuticals Inc.$6K
Otsuka America Pharmaceutical, Inc.$669
Johnson & Johnson$344
Alkermes, Inc.$300
plus $728 from 8 others

What the payments were for

Consulting fees$75,83612%
Speaking & faculty fees$489,04779%
Travel & lodging$35,1346%
Food & beverage$18,6913%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Neurocrine Biosciences, Inc.	492	$572,708
E.r. Squibb & Sons, L.L.C.	43	$38,404
Sunovion Pharmaceuticals Inc.	8	$5,554
Otsuka America Pharmaceutical, Inc.	9	$669
Johnson & Johnson	4	$344
Alkermes, Inc.	5	$300
AbbVie(2 entities)	3	$168
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$139
Indivior Inc.	1	$113
Teva Pharmaceuticals USA, Inc.	4	$89
Neuronetics, Inc.	1	$85
Janssen Scientific Affairs, LLC	2	$54
Bausch Health US, LLC	2	$40
Lundbeck LLC	2	$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$618,708 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York →

Other psychiatry in Baldwin

Leslie CitromePomona$5.7M
Sanjay GuptaCheektowaga$1.9M
Richard PriceMonsey$1.7M
Adam AshtonAmherst$1.6M
Christoph CorrellGlen Oaks$1.5M
Manish ZinzuvadiaNew York$1.3M
George KruseBronx$1.2M
Jianping ChenNew York$1.2M
Horacio CapoteAmherst$1.1M
Yadagiri ChepuruYonkers$963K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →